Brokerage firm JP Morgan Maintains its rating on OvaScience Inc(NASDAQ:OVAS). In a research note issued to the investors, the brokerage major Lowers the price-target to $8.00 per share. The shares have been rated Neutral. The rating by JP Morgan was issued on Aug 5, 2016.
OvaScience Inc (OVAS) shares turned negative on Wednesdays trading session with the shares closing down -0.03 points or -0.49% at a volume of 3,08,828. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.1956. The peak price level was also seen at $6.1956 while the days lowest was $5.85. Finally the shares closed at $6.09. The 52-week high of the shares is $24.435 while the 52-week low is $4.53. According to the latest information available, the market cap of the company is $217 M.
OvaScience Inc(OVAS) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $189.00K. Analysts had an estimated revenue of $190.00K. Earnings per share were $-0.62. Analysts had estimated an EPS of $-0.78.
Several Insider Transactions has been reported to the SEC. On Jun 3, 2016, Richard Aldrich (director) purchased 425,000 shares at $7.00 per share price.Also, On Jun 3, 2016, Michelle Dipp (CEO) purchased 425,000 shares at $7.00 per share price.On May 12, 2016, Paul W.d. Chapman (COO) purchased 3,100 shares at $7.37 per share price, according to the Form-4 filing with the securities and exchange commission.
OvaScience Inc. is a global fertility company. The Company is focused on the discovery development and commercialization of new fertility treatments based on egg precursor or EggPC cells which are immature egg cells found in the protective outer layer of a woman’s own ovaries. With the Company’s AUGMENT treatment energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a woman’s own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.